Filing Details
- Accession Number:
- 0000899243-20-013205
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-15 15:28:09
- Reporting Period:
- 2020-05-13
- Accepted Time:
- 2020-05-15 15:28:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1679082 | Myovant Sciences Ltd. | MYOV | () | M0 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1446601 | Dainippon Sumitomo Pharma Co Ltd | 6-8 Doshomachi 2-Chome Chuo-Ku, Osaka M0 541-0045 | No | No | Yes | No | |
1798244 | Ltd. Biopharma Sumitovant | 11-12 St. James'S Square Suite 1 3Rd Floor London X0 SW1Y 4LB | No | No | Yes | No | |
1798550 | Sumitomo Chemical Co., Ltd. | 27-1, Shinkawa 2-Chome Chuo-Ku, Tokyo M0 104-8260 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-05-13 | 41,331 | $12.38 | 48,418,472 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2020-05-14 | 50,000 | $12.02 | 48,468,472 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Footnotes
- This acquisition of a total of 41,331 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan").
- The price reported in column 4 is the average stock price.
- Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,418,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
- This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan.
- Sumitovant directly owns 48,468,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.